- Significant bioavailability results were reported from LXRP’s randomized, double-blind European study that evaluated its proprietary TurboCBD capsules, powered by DehydraTECH
- Results corroborate and confirm in vitro and in vivo studies of DehydraTECH technology that measured high levels of drug delivery being achieved faster than with matching controls
- LXRP says that it is pleased that DehydraTECH has, to date, repeatedly proved evidence of success within human studies; technology earlier demonstrated ability to deliver nicotine
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is pleased to report significant bioavailability results from its randomized and double-blind European human clinical study of DehydraTECH™ powered TurboCBD™ and cannabidiol (CBD) fortified hemp oil capsules (http://nnw.fm/T7d2E). The new study evaluated the speed and degree of CBD absorption into blood plasma and included cardiovascular and cognitive enhancement in male volunteers.
Results corroborate and confirm earlier in vitro and in vivo studies that evaluated DehydraTECH’s platform and measured higher levels of drug delivery achieved quicker than controls with matching CBD amounts. LXRP said that it believes nearly identical bioavailability enhancement results would be shown if the cannabinoid was THC instead of CBD.
Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology to promote healthier ingestion methods. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio. DehydraTECH is its proprietary absorption technology platform.
In the six hours of the latest study, LXRP’s TurboCBD capsules delivered more CBD to the blood than the positive control capsules at each time point in the study up to its completion.
According to an article published by CFN Media Group, LXRP has applied for a patent to the USPTO, because, in lab studies, the proprietary technology may have proved itself capable of transporting active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier (http://nnw.fm/oN1Xp).
That barrier blocks blood-borne circulating toxins and is a challenge to researchers trying to deliver APIs in medications. The barrier serves as a significant hindrance for drug treatment of diseases of the central nervous system. In lab tests, DehydraTECH was able to transport more nicotine to the brain tissue, conjugating or joining with APIs for maximum delivery.
LXRP has been conducting in vivo lab studies on animals to, in part, determine DehydraTECH’s ability to deliver enhanced levels of nicotine to the bloodstream and brain tissue. The studies found that this platform was able to deliver up to 560 percent greater amounts of nicotine to the brain tissue compared to controls without DehydraTECH. Originally, the tests were focused on developing products for nicotine replacement (http://nnw.fm/z3Dy1).
These studies demonstrated that the DehydraTECH platform could effectively transport drugs, in this case nicotine, across the blood brain barrier. As a result, LXRP filed for a patent for DehydraTECH’s innovative treatment options for diseases and disorders including Alzheimer’s, Huntington’s and Parkinson’s. LXRP hopes to leverage this future possible patent to commercialize its development of future new products that treat central nervous system diseases.
For more information, visit the company’s website at www.LexariaBioscience.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]m
